Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Y-mAbs Therapeutics is a biopharmaceutical company specializing in developing and commercializing innovative antibody-based and radioimmunotherapy cancer treatments. Its core product, DANYELZA, targets GD2-positive tumors, primarily in pediatric neuroblastoma, with ongoing trials for other cancers. The company leverages proprietary platforms and collaborations with leading research institutions to address unmet medical needs in oncology through targeted therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.